Bortezomib

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Bortezomib
Aug 13, 2024, 18:59 | Insight
Michael Makris: Would you give myeloma therapy for MGUS?
Michael Makris, Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on…
Aug 10, 2024, 11:10 | Insight
Shahrin Ahmed: Multiple myeloma treatment with Darzalex Faspro has been approved by the FDA
Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: "Multiple…
Jul 7, 2024, 14:46 | Opinion
Rahul Banerjee: Fascinating 3-way randomized trial of neuromuscular training
Rahul Banerjee, Assistant Professor at UW Medicine, made the following post on X: “This is…
Jul 4, 2024, 14:21 | Insight
A critical appraisal of the long-term follow-up of CASSIOPEIA trial by Manni Mohyuddin
Manni Mohyuddin shared a post on X: "A critical appraisal of the long-term follow-up of…
Jul 3, 2024, 06:28 | Blog
Yelak Biru: Is myeloma science and clinical progress fast or slow?
Yelak Biru, President and CEO at the International Myeloma Foundation, shared on X: "Is myeloma…
Jun 29, 2024, 13:39 | Insight
Myeloma Paper of the Day, June 29th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Real-world analysis of renally impaired…
Jun 20, 2024, 12:25 | Insight
Luciano Costa: Some considerations on long-term follow-up of the CASSIOPEIA trial
Luciano Costa, a Professor at the University of Alabama at Birmingham, recently shared a post…
Jun 7, 2024, 16:50 | Insight
Myeloma Paper of the Day, June 7th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Response rate and EFS to…
Jun 5, 2024, 14:51 | Blog
Diko Kazandjian: IsaVRD more is better
Dickran (Diko) Kazandjian, Professor of Medicine at the Sylvester Comprehensive Cancer Center and Board Member…
Jun 4, 2024, 14:44 | Insight
Myeloma Paper of the Day, June 4th, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: Phase III BENEFIT trial shows…
Jun 2, 2024, 15:31 | Insight
Myeloma Paper of the Day, June 2nd, suggested by Robert Orlowski
Robert Orlowski shared on X: "Myeloma Paper of the Day: DREAMM-7 study shows belantamab/bortezomib/dexamethasone superior…
May 14, 2024, 16:12 | Insight
Myeloma Paper of the Day, May 14th, suggester by Robert Orlowski
Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X: "Myeloma…
May 8, 2024, 02:28 | Insight
Myeloma Paper of the Day, May 7th, suggested by Robert Orlowski
Robert Orlowski, Director of Myeloma Section at MD Anderson Cancer Center, shared on X/Twitter: "Myeloma…
Apr 20, 2024, 05:56 | Insight
Myeloma Paper of the Day suggested by Robert Orlowski, April 18th
Robert Orlowski, Director of the Myeloma Section at MD Anderson Cancer Center, shared on X:…
Mar 1, 2024, 18:37 | Drugs
Vincent Rajkumar: How many years of life gained because of FDA accelerated approval in myeloma?
Vincent Rajkumar, Editor-in-Chief at the Blood Cancer Journal, shared a thread on X/Twitter: "How many…
Jan 6, 2024, 11:43 | Blog
Manni Mohyuddin: Carfilzomib is NOT better than bortezomib for newly diagnosed myeloma
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on…
Dec 24, 2023, 18:13 | Insight
Oncology Brothers: ASH23 Myeloma Highlights with Jens Hillengass:
Oncology Brothers shared on their X/Twitter page: "ASH23 Myeloma Highlights with Jens Hillengass. - PERSEUS…
Aug 13, 2023, 10:01 | Blog,Drugs
Rahul Banerjee: How do we standardize the standard of care for bortezomib (Velcade) in multiple myeloma?
Rahul Banarjee, Assistant Professor in the Division of Medical Oncology at the University of Washington,…
All: 18 Posts: 1 - 100
Special Coverage